Dabt Adam Brockman Ph.D.

Adam Brockman PhD, DABT has extensive experience in translational science, toxicology, pharmacology, DMPK (drug metabolism and pharmacokinetics), and bioanalysis. Adam has held several senior positions in various pharmaceutical and biotech companies.

Currently, Adam is the Senior Director of Translational Science at Aldeyra Therapeutics since June 2022. Prior to that, they served as the Director of Translational Science at the same company from April 2019 to June 2022. In this role, they led the company's translational science efforts, including toxicology, pharmacology, DMPK, bioanalytical, biomarker, and non-clinical studies. Adam played a crucial role in advancing the company's anti-inflammation pipeline, which included ocular and systemic inhibitors.

Previously, Adam worked as the Site Head & Director of US Operations at Cyprotex from January 2018 to May 2019. Adam supervised a team of over 20 staff and oversaw scientific operations within the company's technical teams, operations team, and project management team.

Adam also worked as a Translational Science Consultant at Next Phase Consulting LLC from June 2017 to January 2018. Adam provided expertise in pharmacokinetics, pharmacodynamics, ADME, toxicology, and pharmacology to assist client teams in advancing compounds through various stages of development.

Before that, Adam held positions such as Associate Director NonClinical Development at Inotek Pharmaceuticals Corporation, Head of Pharmacology, Toxicology, & Metabolism at Turing Pharmaceuticals AG, Head of Bioanalysis & DMPK at Placon Therapeutics Inc, and Director of Bioanalytical & DMPK at Normoxys Inc. Adam also worked as a DMPK Professional at Sentrion LLC and a Research Fellow at Merck.

Throughout their career, Adam has demonstrated leadership, collaboration, and expertise in various aspects of drug development, including translational science, toxicology, pharmacology, and DMPK. Adam has contributed to the advancement of multiple projects and has extensive experience in preclinical research, IND submissions, and regulatory affairs.

Adam Brockman, PhD, DABT, received their education from various institutions. Adam began their academic journey at Midlothian High School, although the specific years are not provided. In 1989, they attended Bard College at Simon's Rock, but no degree or field of study is mentioned for this period.

Adam then pursued a Bachelor of Science (BS) in Chemistry at the University of Pittsburgh from 1990 to 1993. Following this, they attended The University of Georgia from 1993 to 1997, where they earned their PhD in Biological Chemistry.

In addition to their extensive education, Adam Brockman obtained the certification "Diplomate of the American Board of Toxicology" from the American Board of Toxicology, Inc. The specific date of achievement is not provided. Adam also attained the certification "DABT" from the same institution in January 2017.